There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Adaptive Biotechnologies (ADPT – Research Report) and Springworks Therapeutics (SWTX – Research Report) with bullish sentiments.
Adaptive Biotechnologies (ADPT)
In a report released yesterday, Daniel Brennan from TD Cowen maintained a Buy rating on Adaptive Biotechnologies, with a price target of $10.00. The company’s shares closed last Tuesday at $7.80, close to its 52-week high of $8.33.
According to TipRanks.com, Brennan is a 5-star analyst with an average return of
Adaptive Biotechnologies has an analyst consensus of Moderate Buy, with a price target consensus of $8.08, a 5.9% upside from current levels. In a report issued on February 10, J.P. Morgan also maintained a Buy rating on the stock with a $8.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Springworks Therapeutics (SWTX)
TD Cowen analyst Yaron Werber maintained a Buy rating on Springworks Therapeutics yesterday and set a price target of $66.00. The company’s shares closed last Tuesday at $55.13, close to its 52-week high of $60.00.
According to TipRanks.com, Werber is a 4-star analyst with an average return of
Currently, the analyst consensus on Springworks Therapeutics is a Strong Buy with an average price target of $67.17, a 25.0% upside from current levels. In a report issued on January 31, Evercore ISI also maintained a Buy rating on the stock with a $60.00 price target.
Read More on ADPT:
- Adaptive Biotechnologies Reports 2024 Financial Performance
- Adaptive Biotechnologies sees FY25 operating expenses $340M-$350M
- Adaptive Biotechnologies reports Q4 EPS (23c), consensus (24c)
- Adaptive Biotechnologies (ADPT) Q4 Earnings Cheat Sheet
- Adaptive, NeoGenomics partner to expand access to disease monitoring
